AIM — AIM ImmunoTech Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 946644 ·
Last close
$0.14
Market Cap
$5.43M
52W High
$1.82
52W Low
$0.12
ADV30
533,858
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 22,000 | 18,000 | -2,226,000 | -3,023,000 | 8,585,000 | 5,816,000 | 6,460,000 |
| Dec 2025 | 21,000 | -19,000 | -2,952,000 | -4,175,000 | 5,782,000 | 2,985,000 | 15,565,000 |
| Sep 2025 | 26,000 | -42,000 | -2,447,000 | -3,284,000 | 5,494,000 | 2,347,000 | 11,571,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,315,000
Investing CF
$918,000
Financing CF
$15,315,000
CapEx
$-413,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.36
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-443,809,000
Inventory
—
Receivables
$0
ST Investments
$63,000
EBIT TTM
$-12,284,000
Pretax Income TTM
$-13,276,000
Interest Exp TTM
$992,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$95,000
EBITDA
$-10,734,000
Free Cash Flow
$-14,060,500
Enterprise Value
$-1,519,298
Total Cash
$9,964,000
Total Debt
$3,921,000
Shares Out
39,919,844
Trailing EPS
$-2.98
Book Value
$-3.19
ROE
-2382.3%
ROA
-82.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 88,000 | -11,664,000 | -13,958,000 | 5,782,000 | 15,565,000 | -9,783,000 | -10,957,000 |
| Dec 2024 | 170,000 | -19,772,000 | -17,320,000 | 8,608,000 | 9,930,000 | -1,322,000 | -14,888,000 |
| Dec 2023 | 202,000 | -31,916,000 | -28,962,000 | 19,381,000 | 9,147,000 | 10,234,000 | -21,267,000 |
| Dec 2022 | 141,000 | -19,923,000 | -19,445,000 | 40,488,000 | 2,020,000 | 38,468,000 | -16,108,000 |
TTM Snapshot
Revenues TTM
$95,000
NetIncome TTM
$-14,270,000
OpCashFlow TTM
—
Assets (Latest)
$12,731,000
Forward EPS
$-0.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZEOX | Zeo ScientifiX, Inc. | $6.27M | $0.80 | — |
| SCLX | Scilex Holding Co | $4.52M | $0.64 | — |
| ALGS | Aligos Therapeutics, Inc. | $7.40M | $1.36 | — |
| CUBT | Curative Biotechnology Inc | $7.56M | $0.85 | — |
| LIMN | Liminatus Pharma, Inc. | $3.77M | $2.81 | — |
News headlines (Yahoo Finance, 1h cache)
AIM ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
2026-11-18 13:30 · Yahoo
AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results
2026-11-13 13:30 · Yahoo
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
2026-11-10 14:20 · Yahoo
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
2026-11-05 14:13 · Yahoo
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
2026-10-07 13:14 · Yahoo
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
2026-10-05 13:22 · Yahoo
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
2026-09-30 12:44 · Yahoo
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
2026-09-22 12:55 · Yahoo
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
2026-09-09 13:03 · Yahoo
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
2026-08-27 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.